NEW YORK, Aug 13 (Reuters) - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...

Pfizer is deeply undervalued, trading at a multi-year low with a 6.65% dividend yield, making it a compelling long-term opportunity. Recent double-digit earnings growth, strong margins, and cost ...